Xenetic Biosciences, Inc. , a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens.
Xenetic Biosciences stock last closed at $0.43, up 1.42% from the previous day, and has decreased 57.43% in one year. It has underperformed other stocks in the Biotechnology industry by 0.34 percentage points. Xenetic Biosciences stock is currently +79.17% from its 52-week low of $0.24, and -65.6% from its 52-week high of $1.25.
At the moment, there are 15.17M XBIO shares outstanding. The market capitalization of XBIO is $6.52M. In the past 24 hours, 21,165 XBIO shares were traded.
How to Buy Xenetic Biosciences Stock
Not sure how to invest in Xenetic Biosciences stock? Here's how.
Figure out where to buy Xenetic Biosciences stock: You need to pick a stock brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you figure out where to buy Xenetic Biosciences stock.
Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
Fund your investment account: Select your method of payment and add your info.
Evaluate Xenetic Biosciences stock: The Xenetic Biosciences ticker symbol is XBIO. Is Xenetic Biosciences stock a good investment? Should you buy shares of XBIO? How do XBIO's underlying business fundamentals look? Do top analysts think Xenetic Biosciences is a good buy? Why has XBIO's stock price moved recently? (Hint: Our stock market research website can help you evaluate if XBIO is a good stock to buy).
Make your XBIO purchase: Decide if you will purchase XBIO shares at the current market price or use a limit order to purchase XBIO stock at a given price.
Monitor your XBIO investment: Create a watchlist to keep tabs on your investment in Xenetic Biosciences stock.
Step 1: Figure out where to buy Xenetic Biosciences stock
You need an online brokerage account in order to access the NASDAQ market and buy XBIO stock.
A brokerage account is an investment account that allows you to buy and sell a variety of financial instruments, including stocks, bonds, mutual funds, and ETFs.
Our preferred brokerage: eToro
We believe that eToro is the best place to buy stocks. Here's why:
Invest in stocks with 0% commissions: Invest without commissions.
Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
Access to global markets: From Tech to Real Estate, New York to Shanghai — you can fill your portfolio with stocks from the world's top stock exchanges.
Social investing: eToro offers a community of more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of top investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by opening an account with eToro today.
After you have figured out the best place to buy Xenetic Biosciences stock, it's crucial to analyze their stock before you buy, so you actually understand the risk as well as the opportunity.
Xenetic Biosciences stock data
XBIO Price
$0.43
1w %
14.97%
1y %
-57.43%
5y %
-98.36%
P/E
-0.84x
P/B
0.45x
P/S
3.98x
PEG
N/A
Revenue
$1.55M
Earnings
-$6.91M
Fore. Rev. Growth
5.05%
Fore. Earn. Growth
N/A
Market Cap
$6.52M
Next Earnings
Apr 3, 2023
Next Dividend
N/A
Fundamentals of XBIO
WallStreetZen was created to help average investors do better fundamental analysis in less time.
XBIO has $13.85M in cash and short term investments. This is enough to cover its annual cash burn of $5.35M.
Total XBIO debt is lower than 5 years ago, relative to shareholder equity.
There are more short-term assets than short-term liabilities on the XBIO balance sheet.
There are more short-term assets than long-term liabilities on the XBIO balance sheet.
XBIO has a low debt to equity ratio of 0.07.
XBIO has cash burn of 5354557. It has enough cash and short-term investments to cover this for at least one year.
Cons:
XBIO profit margin has gone up by 0.66 percentage points in the past year, but the company is still unprofitable.
Is XBIO stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 1 Wall Street analysts who give recommendations on XBIO, the consensus analyst rating on Xenetic Biosciences is a Buy
It's important to note that analyst ratings are not recommendations, nor are they financial advice.
Most Recent XBIO Analyst Ratings
Joseph Pantginis, a bottom 5% analyst from HC Wainwright & Co. maintains XBIO with a buy rating and lowers their XBIO price target from $5.00 to $4.00, on May 2, 2022.
Last year, XBIO revenue was $1.55M. During the past five year, XBIO's revenue has increased by -12.83% per year. This was slower than the Biotechnology industry average of 51.32%.
No, Xenetic Biosciences doesn't provide an income stream by paying out dividends.
What others are saying about XBIO
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Make your XBIO purchase
You have two primary options:
Market order: A market order is an order to buy or sell a security at the best available price. Market orders are generally sufficient.
Limit order: A limit order is an order to buy or sell a security at a specific price (or better). If you want to make sure you're buying or selling at a specific dollar amount limit, use a limit order.
Press the Open Trade button and eToro will place your order.
If you want more help with investing in stocks on eToro, watch the helpful video below:
How much does it cost to buy one Xenetic Biosciences share?
As of Mar 17, 2023, it costs $0.43 to buy one share of Xenetic Biosciences stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $0.22, you can buy 0.5 shares of XBIO.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.